{
    "nctId": "NCT00580112",
    "briefTitle": "An Efficacy Study of Trabectedin in the Treatment of Participants With Specific Subtypes of Metastatic Breast Cancer",
    "officialTitle": "Phase II, Multicenter, Open-label, Clinical Trial of Trabectedin (Yondelis) in Metastatic Breast Cancer Patients With Triple Negative Profile (ER-, PR-, HER2-), HER2 Overexpressing Tumors and BRCA1 or BRCA2 Mutation Carriers",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 127,
    "primaryOutcomeMeasure": "Percentage of Participants With Confirmed Objective Response (OR) by Independent External Review (IER)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Participants with histologically proven diagnosis of progressive metastatic breast cancer\n* Participants with measurable disease as per the Response Evaluation Criteria In Solid Tumors (RECIST) guidelines\n* Participants with bone metastases currently receiving bisphosphonates for palliation will be eligible if other sites of measurable disease are present\n* Participants with Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1 and adequately recovered from the acute toxicity of any prior treatment\n* Participants with serum creatinine less than or equal to 1.5 milligram per deciliter (mg/dl) or creatinine clearance greater than or equal to 30 milliliter per minute (ml/min)\n\nExclusion Criteria:\n\n* Participants with previous exposure to trabectedin\n* Participants with more than 3 previous chemotherapy regimens for metastatic disease and known hypersensitivity to components of trabectedin intravenous formulation or dexamethasone\n* Pregnant or lactating women or any women of childbearing potential who is not employing adequate contraception\n* Completion of previous therapy : Less than 2 weeks from radiation therapy or last dose of hormonal therapy, less than 3 weeks from previous biological therapy or chemotherapy\n* Participants with known leptomeningeal disease and other serious illnesses like congestive heart failure or angina pectoris; myocardial infarction within 1 year before enrolment; uncontrolled arterial hypertension or arrhythmias or active infection or psychiatric disorder or active viral hepatitis",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}